Overview

Azilect® In Wearing-Off (AIWO)

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
End-of-dose fluctuations e. g. wearing-off are defined as a recurrence of motor and non-motor Parkinson's Disease (PD) symptoms that precedes a scheduled dose and improves with the next dose of anti-parkinsonian medication. Azilect® is approved and recommended for therapy of wearing-off-/End-of-dose fluctuations and improves motor fluctuations significantly in combination therapy with L-dopa and other parkinsonian medication.
Details
Lead Sponsor:
Teva Pharma GmbH
Collaborator:
Anfomed GmbH
Treatments:
Rasagiline